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Table S1 An overview on recently reported methods, including nanomaterial-based optical 
methods, for the determination of IL-6 
Recognition 




Limit (pg·mL-1) Reference 
Antibody Photoelectrochemical immunoassay 0.1 – 1.0 x 10
5 0.033 [S1] 
Antibody Electrochemical immunoassay 1.0 x 10
-3 – 9.0 x 103 3.2 x 10-4 [S2] 
Antibody Electrochemiluminescent immunoassay 1.0 x 10
-5 – 9.0 x 103 3.5 x 10-6 [S2] 
Antibody Fluorescence 0.4 – 400 0.1 [S3] 
Antibody Electrochemiluminescent immunoassay 2.0 – 2.0 x 10
4 0.65 [S4] 
Antibody Photoelectrochemical immunoassay 1.0 x 10
−6 – 10.0 0.737 x 10−6 [S5] 
Antibody Magnetic Colorimetric Immunoassay 0.1 – 1.0 x 10
3 0.04 [S6] 
Antibody Immunochromatrographic Strip 62.5 x 10
3 – 2.0 x 106 62.5 x 103 [S7] 
Antibody Liquid-gated field effect transistor 4.7 – 300 1.53 [S8] 
Antibody Photoelectrochemical immunoassay 1.0 – 1.0 x 10
5 0.38 [S9] 
Antibody Electrochemical immunoassay 1.0 x 10
-5 – 100 1.0 x 10-5 [S10] 





AuNP synthesis and characterisation 
Citrate-stabilised gold nanoparticles (cAuNP) of ca. 15 nm were synthesised according to the 
method of Turkevich et al. [S11]. Briefly, aqueous solutions of HAuCl4·3H2O (12.5 mg, 32 
µmol, in 100 mL water) and sodium citrate tribasic dihydrate (50 mg, 168 µmol, in 50 mL water) 
were prepared and heated to 60 °C. The two solutions were rapidly combined while stirring 
vigorously. The temperature was increased to 85 °C and the solution was stirred for 2.5 h, 
resulting in a ruby-red gold nanoparticle solution. After cooling to room temperature, the 
solution was filtered through a Millipore syringe filter unit (0.45 µm). Characterisation was 
performed by UV-Vis as described in the Materials and Equipment section. The particle 




Synthesis of ca. 50 nm cAuNP was performed using the seeded growth method (for AuNPs 
of up to 180 nm) of Bastús et al. [S12]. AuNP seeds (ca. 10 nm) were first prepared by boiling 
an aqueous solution of sodium citrate (150 mL, 2.2 mM) in a three-necked round bottom flask 
under reflux. Once boiling, 1 mL of a 25 mM HAuCl4·3H2O solution (at room temperature) was 
rapidly injected under vigorous stirring. A colour change from pale yellow to bluish grey and 
finally a soft pink occurred within 10 min, signalling the formation of the cAuNP seeds. Larger 
cAuNP synthesis was then performed immediately and in the same reaction vessel. The soft 
pink solution was first cooled to 90 °C. Then, 1 mL of a HAuCl4·3H2O solution (25 mM, at room 
temperature) was injected under vigorous stirring. After 30 min, the reaction was finished, as 
indicated by a colour change from soft pink to ruby red. This process was repeated a further 
two times. Afterward, a dilution step was performed by extracting 55 mL of solution, and 
subsequently adding 53 mL of dH2O and 2 mL of aqeous sodium citrate (60 mM) (both at room 
temperature). All steps were performed at 90 °C under vigorous stirring. This diluted solution 
was then used as a seed solution, and the entire process was repeated again as follows. After 
a short incubation (5 min or less) to allow the added solutions to equilibrate to 90 °C, 1 mL of 
aqueous HAuCl4·3H2O (25 mM, at room temperature) was injected and the solution was 
stirred vigorously (at 90 °C) for 30 min. This process was repeated a further two times, after 
which the dilution step was performed as described previously. A single ‘growth step’ 
comprises of this entire sequence (3x 1 mL of 25 mM HAuCl4·3H2O with 30 min incubation 
between, followed by the dilution step consisting of extraction of 55 mL of solution, and 
addition of 53 mL + 2 mL of additional solutions). A total of six growth steps were performed 
in order to obtain ca. 50 nm cAuNP. The extracted solutions obtained during the dilution steps, 
and the final solution of cAuNP were rapidly cooled to room temperature (on ice) to stop the 
reaction. After cooling, the solution was filtered through a Miller GP syringe driven filter unit 
(0.45 µm). Characterisation of the extracted and final solutions were performed by UV-Vis as 
described in the Materials and Equipment section, enabling the growth of the AuNP to be 
monitored. The particle concentration in the final ca. 50 nm cAuNP solution was approximately 
0.2 nM [S12].  
TEM was used to establish the size and morphology of the ca. 15 and 50 nm cAuNP. 10 µL 
of the cAuNP in solution was placed onto a holey carbon film 300 mesh copper grid. Excess 
solution was removed from the sample by touching the side of the grid with adsorbent tissue 
paper. The grid was dried overnight at room temperature before analysis by TEM, as 
previously described. Size measurement of the cAuNP was performed using ImageJ software. 
DLS size measurements of the 15 nm cAuNP were performed on a Malvern Zetasizer, as 
described previously. Size measurements were recorded at 25 °C, with a backscattering and 
forward scattering angles of detection (173° and 13°). Water was selected as the dispersant 
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with viscosity and refractive index (RI) of 0.8872 cP and 1.330 cP, respectively. Measurements 
of the 50 nm cAuNP were performed in a DynoPro (DLS) Plate Reader II using Corning 96-
well plastic-bottom plates (200 µL of sample/well), at 24 °C and with a 100 sec acquisition time 




Table S2 Composition of the ‘representative biological matrix’ - concentrations of the human 
cytokine and chemokine standards present in the mixed protein stock solution (in Universal 
Assay Buffer with 0.5 mg·mL-1 HSA) 












































Results and Discussion 
AuNP synthesis and characterisation 
TEM is used to visualise the 15 and 50 nm cAuNP (shown in Fig. S1a and d, respectively). 
The average diameters of the cAuNP, measured from the TEM images, are 15.0 ± 1.3 nm and 
53.0 ± 5.2 nm (n = 100) (Fig. S1b and e). DLS is also used to estimate the size of the cAuNP. 
The average sizes of the cAuNP, estimated by DLS, are 16.5 ± 0.21 nm and 55.4 ± 1.9 nm 
(based on 3 repeat measurements per sample). cAuNP absorb light in the visible spectrum 
with a maximum absorption intensity and wavelength that are size-dependent. For the 15 nm 
cAuNP, the surface plasmon absorption band exhibits a maximum at ca. 520 nm, yielding a 
spectrum as shown in Fig. S1c. For the 50 nm cAuNP, the surface plasmon absorption band 
exhibits a maximum at approximately 540 nm, as demonstrated in Fig. S1f. The binding of the 
aptamers to the surface of the AuNP is demonstrated by a shift in the absorption wavelength 
of approximately 3-4 nm following functionalisation, as shown in Fig. S1c and f for 15 nm and 
50 nm AuNPs, respectively. This shift to the red region of the spectrum is indicative of 
modification of the surface of the AuNP, resulting in a size increase which is reflected by 
increased absorption wavelength. The increase in particle size following addition of aptamers 
to the AuNP surface is also determined by DLS, yielding an average size increase (post-
functionalisation) of 38.8 ± 5.1 nm (see Table S3 for complete DLS results). These results 







Fig. S1 Characterisation of the aptamer-AuNP by TEM and UV-Vis spectrophotometry. TEM 
images of the 15 and 50 nm citrate AuNP are shown in (a) and (d), respectively. The average 
sizes of the cAuNP, estimated from the TEM images (n = 100), were 15.0 ± 1.3 nm (b) and 
53.0 ± 5.2 nm (e). UV-Vis absorption spectra of the 15 and 50 nm cAuNP and aptamer-AuNP 
are shown in (c) and (f), respectively. Addition of aptamers to the AuNP surface led to a red 
shift in the absorption maxima (at ca. 520 nm for the 15 nm AuNP, and ca. 540 nm for the 50 




Table S3 The particle size of: ca. 15 and 50 nm cAuNP, aptamer-functionalised AuNP, and 
aggregation assay solutions (as determined by DLS) 
Sample Average Diameter ± SD (nm) 
ca. 15 nm cAuNP 16.50 ± 0.11 
ca. 15 nm aptamer-AuNP 55.96 ± 5.30 
ca. 50 nm cAuNP 54.58 ± 1.00 
ca. 50 nm aptamer-AuNP 93.40 ± 5.07* 
ca. 50 nm mixed aptamer-AuNP:  
buffer test control (without IL-6) 84.43 ± 3.92* 
ca. 50 nm mixed aptamer-AuNP:  
buffer test (with 109.4 µg·mL-1 IL-6) 632.29 ± 137.62 
ca. 50 nm mixed aptamer-AuNP: 
“representative sample” buffer control 
(without IL-6) 
94.17 ± 23.18 
ca. 50 nm mixed aptamer-AuNP: 
“representative sample” negative 
control (without IL-6) 
97.18 ± 19.58 
ca. 50 nm mixed aptamer-AuNP: 
“representative sample” test  
(with 125 µg·mL-1 IL-6) 
479.02 ± 211.92* 






Aggregation assay results – detecting IL-6 standard solutions 
The aggregation assay is performed titrating increasing volumes of IL-6 in a mixed protein 
solution broadly representative of a biological matrix (see Table S2 for detailed composition 
of the matrix – components include human serum albumin and 36 arbitrary human cytokines 
and chemokines). A decrease in the absorption intensity at the λmax (ca. 540 nm) and a red 
shift in the absorption maximum are observed in response to increasing IL-6 concentration 
(from 0 to 125 μg·mL-1), confirming the aggregation of the aptamer-AuNP. Two buffers are 
used as control: 1) a buffer containing HSA only (‘buffer control’), and 2) a buffer containing 
both HSA and the human protein mix (‘negative control’). No changes in the absorption 
intensity at the λmax (ca. 540 nm) are observed when equal volumes of the controls are added 
to the aptamer-AuNP. The aggregation of the particles in the presence of IL-6 in the mixed 
protein matrix is confirmed by a visual colour change (Fig. S2 – right) that is not observed 
when the particles were treated with the ‘buffer control’ (Fig. S2 – left). 
 
 
Fig. S2 The visible colour change of the final test solution (containing 125 µg·mL-1 IL-6), 
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